

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 17 to 36 OF 2018**

Statements of Principles (SOPs) Nos. 17 to 36 of 2018 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 2 March 2018.

The Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). The day of commencement as specified in each of the Instruments is 2 April 2018. In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument’s registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from: [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Instrument, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the new SOP template which commenced in 2015. This document is available on the Authority's website <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

12 March 2018

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Codes** |
| **REVOCATIONS** |
| 17 & 18/2018 | personality disorder | 02/04/2018 | F60.0, F60.1, F21, F60.2, F60.31, F60.4, F60.8, F60.6, F60.7, F60.5 or F60.9  |
|  |  |  |  |
| 19 & 20/2018 | toxic retinopathy | 02/04/2018 | Nil |
|  |  |  |  |
| 21 & 22/2018 | accidental hypothermia | 02/04/2018 | T68 |
|  |  |  |  |
| 23 & 24/2018 | Guillain-Barre syndrome | 02/04/2018 | G61.0 |
|  |  |  |  |
| 25 & 26/2018 | systemic sclerosis | 02/04/2018 | M34 |
|  |  |  |  |
| 27 & 28/2018 | malignant neoplasm of the eye | 02/04/2018 | C69.0, C69.1, C69.2, C69.3, C69.4, C69.8, C69.9 or D09.2 |
|  |  |  |  |
| 29 & 30/2018 | chilblains | 02/04/2018 | T69.1 |
|  |  |  |  |
| **DETERMINATIONS** |
|  |  |  |  |
| 31 & 32/2018 | popliteal cyst | 02/04/2018 | M66.0 or M71.2  |
|  |  |  |  |
| **AMENDMENTS** |
|  |  |  |  |
| 33 & 34/2018 | suicide and attempted suicide | 02/04/2018 | N/A |
|  |  |  |  |
| 35 & 36/2018 | malignant neoplasm of the ovary | 02/04/2018 | N/A |

**Note**

* The investigation concerning 'toxic maculopathy' has resulted in the determination of Statements of Principles concerning toxic retinopathy.
* The investigation concerning 'Baker's cyst' has resulted in the determination of Statements of Principles concerning popliteal cyst.
* As a result of becoming aware of a minor typographical error in each of the Statements of Principles concerning **malignant neoplasm of the ovary** determined at the December 2017 RMA meeting, the Authority determined to correct the Statements of Principles with the amendment above.

| **SUMMARY OF CHANGES** |
| --- |
| 17 & 18/2018 | personality disorder | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 3 May 2016 concerning *personality disorder* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument Nos. 1 & 2/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'personality disorder' in subsection 7(2);
* revising ICD-10-AM codes for 'personality disorder' in subsection 7(3);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(5) concerning 'a category 1A stressor', by inclusion of a note;
* revising the factors in subsections 9(2) & 9(6) concerning 'a category 1B stressor', by inclusion of a note;
* revising the factors in subsections 9(3) & 9(7) concerning 'severe childhood abuse', by inclusion of a note;
* new factors in subsections 9(4) & 9(8) concerning 'a clinically significant disorder of mental health';
* deleting the factors concerning 'a clinically significant psychiatric condition' and 'a clinically significant attention-deficit and disruptive behaviour disorder' as they are now covered by the factors in subsections 9(4) & (8) concerning 'a clinically significant disorder of mental health';
* new definitions of 'clinically significant disorder of mental health as specified', 'DSM-5', 'MRCA', 'personality change due to another medical condition' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'category 1A stressor', 'eyewitness' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a clinically significant attention-deficit and disruptive behaviour disorder', 'a clinically significant psychiatric condition as specified' and 'DSM-IV-TR'.

**The determining of these Instruments finalises the investigation in relation to *personality disorder* as advertised in the Government Notices Gazette of 3 May 2016.** |
| 19 & 20/2018 | toxic retinopathy | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *toxic maculopathy* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:***For RH SoP*** ***(Instrument No. 19/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'toxic retinopathy';
* revising the definition of 'toxic retinopathy' in subsection 7(2);
* new factor in subsection 9(1) concerning 'being treated with a quinoline-based drug';
* revising the factor in subsection 9(2) concerning 'being treated with tamoxifen';
* new factor in subsection 9(3) concerning 'being treated with an intravitreal or subconjunctival aminoglycoside';
* new factor in subsection 9(4) concerning 'being treated with intravitreal fomivirsen or ganciclovir';
* new factor in subsection 9(5) concerning 'being treated with intravenous deferoxamine';
* revising the factor in subsection 9(6) concerning 'being treated with a phenothiazine';
* revising the factor in subsection 9(7) concerning 'being treated with daily clofazimine';
* new factor in subsection 9(8) concerning 'being treated with ritonavir';
* new factor in subsection 9(9) concerning 'being treated with interferon';
* new factor in subsection 9(10) concerning 'being treated with daily topiramate';
* revising the factor in subsection 9(11) concerning 'having iron chelating therapy';
* new factor in subsection 9(12) concerning 'haematological or biochemical evidence of poisoning with cobalt';
* new factor in subsection 9(13) concerning 'taking oral canthaxanthin supplements or tablets';
* new factor in subsection 9(14) concerning 'inhaling isopropyl nitrite';
* new factor in subsection 9(15) concerning 'using an intravenous drug containing talc';
* new factor in subsection 9(16)(a) concerning 'being treated with daily niacin', for cystoid macular oedema only;
* new factor in subsection 9(16)(b) concerning 'being treated with intravenous paclitaxel or docetaxel', for cystoid macular oedema only;
* new factor in subsection 9(16)(c) concerning 'being treated with the thiazolidinedione drugs rosiglitazone or pioglitazone', for cystoid macular oedema only;
* new factor in subsection 9(17)(a) concerning 'being treated with topical adrenaline eye drops', for cystoid macular oedema only, in an aphakic or pseudophakic eye only;
* new factor in subsection 9(17)(b) concerning 'being treated with latanoprost', for cystoid macular oedema only, in an aphakic or pseudophakic eye only;
* deleting the factor concerning 'being treated with chloroquine, hydroxychloroquine or mepacrine' as it is now subsumed by the factor in subsection 9(1) concerning 'being treated with a quinoline-based drug';
* deleting the factor concerning 'intravitreal gentamicin, amikacin or fomivirsen' as it is now subsumed by the factors in subsections 9(3) & 9(4) concerning 'being treated with an intravitreal or subconjunctival aminoglycoside' and 'being treated with intravitreal fomivirsen or ganciclovir', respectively;
* new definitions of 'aphakic or pseudophakic eye', 'being treated with a quinoline-based drug as specified', 'being treated with tamoxifen as specified', 'cystoid macular oedema', 'MRCA', 'specified list of aminoglycosides', 'specified list of phenothiazines', 'taking oral canthaxanthin supplements or tablets as specified' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'iron chelating therapy as specified' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a phenothiazine as specified' and 'being treated with chloroquine, hydroxychloroquine or mepacrine as specified'.

***For BoP SoP*** ***(Instrument No. 20/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'toxic retinopathy';
* revising the definition of 'toxic retinopathy' in subsection 7(2);
* new factor in subsection 9(1) concerning 'being treated with a quinoline-based drug';
* revising the factor in subsection 9(2) concerning 'being treated with tamoxifen';
* new factor in subsection 9(3) concerning 'being treated with an intravitreal or subconjunctival aminoglycoside';
* new factor in subsection 9(4) concerning 'being treated with intravitreal fomivirsen';
* new factor in subsection 9(5) concerning 'being treated with intravenous deferoxamine';
* revising the factor in subsection 9(6) concerning 'being treated with the phenothiazine drugs chlorpromazine or thioridazine ';
* revising the factor in subsection 9(7) concerning 'being treated with daily clofazimine';
* new factor in subsection 9(8) concerning 'being treated with ritonavir';
* new factor in subsection 9(9) concerning 'being treated with interferon';
* new factor in subsection 9(10) concerning 'being treated with subcutaneous or intramuscular deferoxamine';
* new factor in subsection 9(11) concerning 'taking oral canthaxanthin supplements or tablets';
* new factor in subsection 9(12) concerning 'inhaling isopropyl nitrite';
* new factor in subsection 9(13) concerning 'using an intravenous drug containing talc';
* new factor in subsection 9(14)(a) concerning 'being treated with daily niacin', for cystoid macular oedema only;
* new factor in subsection 9(14)(b) concerning 'being treated with intravenous paclitaxel or docetaxel', for cystoid macular oedema only;
* new factor in subsection 9(15) concerning 'being treated with topical adrenaline eye drops', for cystoid macular oedema only, in an aphakic or pseudophakic eye only;
* deleting the factor concerning 'being treated with chloroquine, hydroxychloroquine or mepacrine' as it is now subsumed by the factor in subsection 9(1) concerning 'being treated with a quinoline-based drug';
* deleting the factor concerning 'intravitreal gentamicin, amikacin or fomivirsen' as it is now subsumed by the factors in subsections 9(3) & 9(4) concerning 'being treated with an intravitreal or subconjunctival aminoglycoside' and 'being treated with intravitreal fomivirsen', respectively;
* new definitions of 'aphakic or pseudophakic eye', 'being treated with a quinoline-based drug as specified', 'being treated with tamoxifen as specified', 'cystoid macular oedema', 'MRCA', 'specified list of aminoglycosides', 'taking oral canthaxanthin supplements or tablets as specified' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a phenothiazine as specified' and 'being treated with chloroquine, hydroxychloroquine or mepacrine as specified'.

**The determining of these Instruments finalises the investigation in relation to *toxic maculopathy* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 21 & 22/2018 | accidental hypothermia | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *accidental hypothermia* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:***For RH& BoP SoPs*** ***(Instrument Nos. 21 & 22/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'accidental hypothermia' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'being exposed to low environmental temperature';
* new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service' in Schedule 1 – Dictionary.

**The determining of these Instruments finalises the investigation in relation to *accidental hypothermia* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 23 & 24/2018 | Guillain-Barre syndrome | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 10 January 2017 concerning *Guillain-Barre syndrome* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:***For RH SoP*** ***(Instrument No. 23/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'Guillain-Barre syndrome' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'having an infection';
* revising the factor in subsection 9(3) concerning 'having a clinically apparent herpes zoster or herpes simplex infection';
* new factor in subsection 9(4) concerning 'having a symptomatic gastrointestinal or respiratory tract infection';
* revising the factor in subsection 9(5) concerning 'receiving an influenza vaccine or a nerve tissue derived rabies vaccine';
* revising the factor in subsection 9(6) concerning 'having a malignant neoplasm';
* revising the factor in subsection 9(7) concerning 'having a solid organ or stem cell transplant';
* new factor in subsection 9(9) concerning 'being treated with a tumour necrosis factor-α inhibitor';
* new factor in subsection 9(10) concerning 'having systemic lupus erythematosus';
* deleting the factor concerning 'having Hodgkin's lymphoma or non-Hodgkin's lymphoma' as it is subsumed by the factor in subsection 9(6) concerning 'having a malignant neoplasm';
* new definitions of 'MRCA', 'specified list of infections' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service', by the inclusion of a note, in Schedule 1 - Dictionary; and
* deleting the definitions of 'an infection from the specified list' and 'a specified vaccine'.

***For BoP SoP*** ***(Instrument No. 24/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'Guillain-Barre syndrome' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'having an infection';
* revising the factor in subsection 9(3) concerning 'having a clinically apparent herpes zoster infection';
* new factor in subsection 9(4) concerning 'having a symptomatic gastrointestinal or respiratory tract infection';
* revising the factor in subsection 9(5) concerning 'receiving an influenza vaccine or a nerve tissue derived rabies vaccine';
* revising the factor in subsection 9(6) concerning 'having a malignant neoplasm';
* revising the factor in subsection 9(7) concerning 'having a solid organ or stem cell transplant';
* new factor in subsection 9(8) concerning 'being treated with a tumour necrosis factor-α inhibitor';
* deleting the factor concerning 'having Hodgkin's lymphoma or non-Hodgkin's lymphoma' as it is subsumed by the factor in subsection 9(6) concerning 'having a malignant neoplasm';
* new definitions of 'MRCA', 'specified list of infections' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service', by the inclusion of a note, in Schedule 1 - Dictionary; and
* deleting the definitions of 'an infection from the specified list' and 'a specified vaccine'.

**The determining of these Instruments finalises the investigation in relation to *Guillain-Barre syndrome* as advertised in the Government Notices Gazette of 10 January 2017.** |
| 25 & 26/2018 | systemic sclerosis | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *systemic sclerosis* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:***For RH SoP*** ***(Instrument No. 25/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'systemic sclerosis' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(3) & 9(7) concerning 'inhaling, ingesting or having cutaneous contact with an organic solvent';
* new factors in subsections 9(4) & 9(8) concerning 'being treated with an ergot alkaloid for migraine';
* new factor in subsection 9(9) concerning 'being treated with 15 milligrams or more per day of prednisone, or equivalent oral glucocorticoid therapy', for clinical worsening of systemic sclerosis manifesting as scleroderma renal crisis only;
* new factor in subsection 9(10) concerning 'smoking', for clinical worsening only;
* deleting the factors concerning 'inhaling, ingesting or having cutaneous contact with trichloroethylene' as they are subsumed by the factors in subsections 9(3) & 9(7) concerning 'inhaling, ingesting or having cutaneous contact with an organic solvent';
* new definitions of 'equivalent oral glucocorticoid therapy', 'ergot alkaloid', 'MRCA', 'pack-years of cigarettes, or the equivalent thereof in other tobacco products', 'scleroderma renal crisis', 'specified list of organic solvents' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service' in Schedule 1 – Dictionary.

***For BoP SoP*** ***(Instrument No. 26/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'systemic sclerosis' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* new factor in subsection 9(7) concerning 'being treated with 15 milligrams or more per day of prednisone, or equivalent oral glucocorticoid therapy', for clinical worsening of systemic sclerosis manifesting as scleroderma renal crisis only;
* new definitions of 'equivalent oral glucocorticoid therapy', 'MRCA', 'scleroderma renal crisis' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service' in Schedule 1 – Dictionary.

**The determining of these Instruments finalises the investigation in relation to *systemic sclerosis* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 27 & 28/2018 | malignant neoplasm of the eye | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *malignant neoplasm of the eye* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:***For RH SoP*** ***(Instrument No. 27/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'malignant neoplasm of the eye' in subsection 7(2);
* revising ICD-10-AM codes for 'malignant neoplasm of the eye' in subsection 7(3);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'sunlight or ultraviolent light exposure';
* revising the factor in subsection 9(2) concerning 'ultraviolet radiation exposure from an ultraviolet-emitting tanning device';
* new factor in subsection 9(4) concerning 'immunosuppressive drug';
* revising the factor in subsection 9(5) concerning 'solid organ or stem cell transplantation';
* revising the factor in subsection 9(6)(a) concerning 'using manual welding equipment for welding metal', for uveal melanoma of the eye only;
* new factor in subsection 9(6)(b) concerning 'exposure to transformer or capacitor oils containing polychlorinated biphenyls', for uveal melanoma of the eye only;
* new factor in subsection 9(7)(a) concerning 'ultraviolet radiation exposure from whole body PUVA therapy', for melanoma of the eye only;
* new factor in subsection 9(7)(b) concerning 'photokeratitis', for melanoma of the eye only;
* new factor in subsection 9(8) concerning 'conjunctival transplant', for conjunctival melanoma of the eye only;
* revising the factor in subsection 9(9)(a) concerning 'acquiring persistent infection of the epithelium of the conjunctiva with a specified human papilloma virus (HPV)', for squamous cell carcinoma of the cornea or the conjunctiva only;
* new factor in subsection 9(9)(b) concerning 'ultraviolet radiation exposure from whole body PUVA therapy', for squamous cell carcinoma of the cornea or the conjunctiva only;
* new factor in subsection 9(9)(c) concerning 'being treated with voriconazole', for squamous cell carcinoma of the cornea or the conjunctiva only;
* new factor in subsection 9(10) concerning 'ocular prosthesis in an anophthalmic socket', for squamous cell carcinoma of the conjunctiva only;
* new definitions of 'MRCA', 'photokeratitis', 'specified human papilloma virus (HPV)', 'unprotected eye', 'VEA' and 'whole body PUVA' in Schedule 1 - Dictionary;
* revising the definitions of 'immunosuppressive drug' and 'relevant service' in Schedule 1 - Dictionary.

***For BoP SoP*** ***(Instrument No. 28/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'malignant neoplasm of the eye' in subsection 7(2);
* revising ICD-10-AM codes for 'malignant neoplasm of the eye' in subsection 7(3);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'sunlight or ultraviolent light exposure';
* revising the factor in subsection 9(2) concerning 'ultraviolet radiation exposure from an ultraviolet-emitting tanning device';
* new factor in subsection 9(4) concerning 'immunosuppressive drug';
* revising the factor in subsection 9(5) concerning 'solid organ or stem cell transplantation';
* revising the factor in subsection 9(6) concerning 'using manual welding equipment for welding metal', for uveal melanoma of the eye only;
* new factor in subsection 9(7) concerning 'photokeratitis', for melanoma of the eye only;
* new factor in subsection 9(8) concerning 'conjunctival transplant', for conjunctival melanoma of the eye only;
* new factor in subsection 9(9)(a) concerning 'ultraviolet radiation exposure from whole body PUVA therapy', for squamous cell carcinoma of the cornea or the conjunctiva only;
* new factor in subsection 9(9)(b) concerning 'being treated with voriconazole', for squamous cell carcinoma of the cornea or the conjunctiva only;
* new factor in subsection 9(10) concerning 'ocular prosthesis in an anophthalmic socket', for squamous cell carcinoma of the conjunctiva only;
* new definitions of 'MRCA', 'photokeratitis', 'unprotected eye', 'VEA' and 'whole body PUVA' in Schedule 1 - Dictionary;
* revising the definitions of 'immunosuppressive drug' and 'relevant service' in Schedule 1 - Dictionary.

**The determining of these Instruments finalises the investigation in relation to *malignant neoplasm of the eye* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 29 & 30/2018 | chilblains | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 3 May 2016 concerning *chilblains* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the revoked Instruments. Comparing these Instruments and the revoked Instruments, the differences include:***For RH SoP*** ***(Instrument No. 29/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'chilblains' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(2) concerning 'having a disease from the specified list of diseases';
* new factor in subsection 9(3) concerning 'body mass index';
* deleting the factor concerning 'having a disease from the specified list', for clinical worsening only;
* new definitions of 'BMI', 'MRCA', 'specified list of diseases' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'a disease from the specified list'.

***For BoP SoP*** ***(Instrument No. 30/2018)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'chilblains' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'exposing the affected part of the body to non-freezing temperatures';
* revising the factor in subsection 9(2) concerning 'having a disease from the specified list of diseases';
* new factor in subsection 9(3) concerning 'body mass index';
* deleting the factor concerning 'having a disease from the specified list', for clinical worsening only;
* new definitions of 'BMI', 'MRCA', 'specified list of diseases' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definition of 'a disease from the specified list'.

On 16 October 2017, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors relating to ***having a disease from the specified list***, for clinical worsening only. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instrument prior to its determination. No submissions were received for consideration by the Authority. Minor changes were made to the proposed Instruments following this consultation process.**The determining of these Instruments finalises the investigation in relation to *chilblains* as advertised in the Government Notices Gazette of 3 May 2016.** |
| 31 & 32/2018 | popliteal cyst | **New Condition****The determining of these new Instruments finalises the investigation in relation to *Baker's cyst* as advertised in the Government Notices Gazette of 10 January 2017.** |
| 33 & 34/2018 | suicide & attempted suicide | **Amendment**These instruments amend Statements of Principles Nos. 65 & 66 of 2016, as amended, concerning ***suicide and attempted suicide*** by:***For RH Amendment SoP*** ***(Instrument No. 33/2018)**** specifies a day of commencement for the amendment;
* replacing the existing factor in subsection 9(11) concerning 'a category 2 stressor';
* incorporating an additional note (Note 1) with the factor in subsection 9(11) concerning 'a category 2 stressor';
* deleting the existing factor in subsection 9(11a) concerning 'a problem with a long-term relationship', as it is subsumed by the factor in subsection 9(11); and
* replacing the existing definition of 'category 2 stressor' in Schedule 1 – Dictionary.

***For BoP Amendment SoP*** ***(Instrument No. 34/2018)**** specifies a day of commencement for the amendment;
* replacing the existing factor in subsection 9(8) concerning 'a category 2 stressor';
* incorporating an additional note (Note 1) with the factor in subsection 9(8) concerning 'a category 2 stressor';
* deleting the existing factor in subsection 9(8a) concerning 'a problem with a long-term relationship', as it is subsumed by the factor in subsection 9(8); and
* replacing the existing definition of 'category 2 stressor' in Schedule 1 – Dictionary.

**The determining of these Instruments finalises the investigation in relation to *suicide and attempted suicide* as advertised in the Government Notices Gazette of 29 August 2017.** |
| 35 & 36/2018 | malignant neoplasm of the ovary | **Amendment**These instruments amend Statements of Principles Nos. 9 & 10 of 2018 concerning ***malignant neoplasm of the ovary*** by:***For RH Amendment SoP*** ***(Instrument No. 35/2018)**** specifies a day of commencement for the amendment;
* amending a typographical error involving a cross reference to a factor in the Statement of Principles. In particular in subsection 10(2) this was an incorrect cross reference to subsection 9(11) when subsection 9(12) was intended.

***For BoP Amendment SoP*** ***(Instrument No. 36/2018)**** specifies a day of commencement for the amendment;
* amending a typographical error involving a cross reference to a factor in the Statement of Principles. In particular in subsection 10(2) this was an incorrect cross reference to subsection 9(8) when subsection 9(9) was intended.

**These Instruments more accurately state the results of an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *malignant neoplasm of the ovary* in accordance with section 196G of the VEA. The determining of Statements of Principles Instrument Nos. 9 & 10 of 2018 and Amendment Statements of Principles Instrument Nos. 35 & 36 of 2018 finalises the investigation in relation to *malignant neoplasm of the ovary* as advertised in the Government Notices Gazette of 19 October 2016.** |